EUVIMEDEUVIMED entdecken
LeserbriefFallbericht

Upadacitinib as a Therapeutic Option for Scleredema Diabeticorum: A Case Report

Hsin-Yi Huang, Yonglan Wu, Xianlin Zeng, Man Li

International Journal of Dermatology · 10.06.2026

DOI: 10.1111/ijd.70536 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Dermatology, online erschienen am 10.06.2026. Verfasst von Hsin-Yi Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Longyan City Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsdiabetes mellitusscleredema adultorum

Autor:innen und Institutionen

  • Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Hematology and Rheumatology, Longyan Second Hospital, Longyan, China.

Förderung

  • Longyan City Science and Technology Plan Project

Zitieren

APA

Huang, H. Y., Wu, Y., Zeng, X., & Li, M. (2026). Upadacitinib as a Therapeutic Option for Scleredema Diabeticorum: A Case Report. International Journal of Dermatology. https://doi.org/10.1111/ijd.70536

Vancouver

Huang HY, Wu Y, Zeng X, Li M. Upadacitinib as a Therapeutic Option for Scleredema Diabeticorum: A Case Report. International Journal of Dermatology. 2026. doi:10.1111/ijd.70536

BibTeX
@article{Huang2026,
  author = {Huang, Hsin-Yi and Wu, Yonglan and Zeng, Xianlin and Li, Man},
  title = {Upadacitinib as a Therapeutic Option for Scleredema Diabeticorum: A Case Report},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70536}
}
Kostenlos starten →